Alle Meldungen
Abonnieren Sie alle Meldungen von Stada Arzneimittel

07.06.2019 – 11:09

Stada Arzneimittel

Press Release: STADA to acquire branded OTC portfolio from GSK to strengthen skin care business in Europe

Press Release: STADA to acquire branded OTC portfolio from GSK to strengthen skin care business in Europe
  • Bild-Infos
  • Download

Ein Dokument

Press Release

STADA to acquire branded OTC portfolio from GSK to strengthen skin care business in Europe

- Acquisition of six brands, five skin care/topical application and one 
  pediatric cough remedy   
- Manufacturing will be transferred to STADA affiliate Thornton & Ross, 
  Huddersfield (UK)   
- CEO Peter Goldschmidt: "STADA becomes the go-to partner in the European 
  market."    

Bad Vilbel, June 7, 2019 - The STADA Group continues to expand its Consumer Health business in Europe and selected markets in APAC and Latin America with a contract to acquire five skin care brands as well as a pediatric cough remedy from GlaxoSmithKline, completion of which is expected to occur in August 2019. "This will strengthen STADA's position as a go-to partner in the European Healthcare market, and will seize the opportunity to be a leading company in Consumer Health as well as Generics", says CEO Peter Goldschmidt.

With exception of a few specialized SKU's, the entire production of the five skin care products to be acquired will be transferred to Thornton & Ross where there is a strong fit with existing portfolio and expertise. "We look forward to giving these great brands a new home and a great future", summarized Roger Scarlett-Smith, who is the Head and Executive Vice President of STADA's UK business and was GSK's Head of Global Categories until September 2016.

The portfolio to be acquired from GSK includes the following products, all of which have strong brand heritage with the opportunity for accelerated revitalization and growth.

Oilatum brand is a full emollient range that accounts for 50% of sales and generates significant sales in Europe, especially in the UK and Poland, as well as helping to build up significant growth in the APAC region.

Eurax is a topical itch relief cream with significant sales in France, Italy and Norway as well as the United Kingdom, Ireland and Hong Kong.

Savlon Antiseptic Cream is a well-known UK brand with strong loyalty.

Ceridal is a specialized skin care brand with sales focus in Finland and Denmark.

Tixylix range of paediatric cough liquids is an established UK brand.

Polytar is a coal-tar based dandruff shampoo sold in the UK. In Spain and Portugal it is known under the brand name Tarmed. Polytar/Tarmed is a medical treatment of scalp conditions including psoriasis. This is a good addition to STADA's hair scalp portfolio, which includes Nizoral and Hedrin.

Caption to supplied picture:

Roger Scarlett-Smith, who is the Head and Executive Vice President of STADA's UK business: "We look forward to giving these great brands a new home and a great future."

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription Consumer Health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 130 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG 
Media Relations 
Stadastrasse 2-18 
61118 Bad Vilbel - Germany 
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215 
E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:
STADA Arzneimittel AG
Investor & Creditor Relations
Stadastrasse 2-18 
61118 Bad Vilbel - Germany 
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215 
E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations 

Alle Meldungen
Abonnieren Sie alle Meldungen von Stada Arzneimittel
  • Druckversion
  • PDF-Version